New Drug Evaluation - Fast acting insulin lispro for the treatment of diabetes mellitus

19th Mar 2021

The New Drug Evaluation for fast acting insulin lispro (Lyumjev) for the treatment of diabetes mellitus is now available to stakeholders. This publication provides a concise, structured evaluation of the efficacy, safety, and potential place in therapy for this newly licensed product.